Clinical Trials in Arizona

Showing 14741-14760 of 16,770 trials

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

NCT00904826

The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.

Neuromyelitis OpticaDevic's Disease

Mayo Clinic14 participantsStarted Apr 2009

Scottsdale, Arizona, United States • Rochester, Minnesota, United States

COMPLETEDPhase 242 miles

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

NCT00663936

The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment. The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.

Alzheimer's Disease

FUJIFILM Toyama Chemical Co., Ltd.373 participantsStarted Apr 2008

Phoenix, Arizona, United States • Tucson, Arizona, United States • Garden Grove, California, United States +32 more locations

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Find Trials by Condition in Arizona

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

3-AP in Treating Patients With Advanced Prostate Cancer

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum